Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

NCT04083963 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Doxorubicin
DRUG: Cyclophosphamide

Sponsor

University of Illinois at Chicago